CD4 and neoplasm: The increase of tumor‐infiltrating T lymphocytes (TILs) predicts a favorable response to immunotherapy.[27] FSP‐RZ‐BPH significantly increased the number of TILs, including CD4+ and CD8+ TILs (Figure 5g–i).